Enteric-coated Mycophenolate Sodium

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Autoimmune Disease

Conditions

Autoimmune Disease

Trial Timeline

Jun 1, 2006 → Jun 1, 2009

NCT ID

NCT00351377

About Enteric-coated Mycophenolate Sodium

Enteric-coated Mycophenolate Sodium is a phase 3 stage product being developed by Novartis for Autoimmune Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00351377. Target conditions include Autoimmune Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01467011	Pre-clinical	Completed	Dec 1, 2010	Dec 1, 2013	End Stage Liver Disease
NCT00351377	Phase 3	Completed	Jun 1, 2006	Jun 1, 2009	Autoimmune Disease
NCT00171379	Phase 3	Completed	Mar 1, 2004	Jun 1, 2005	Prevention of Acute Rejection After Kidney Transplantation
NCT00171392	Phase 3	Completed	Mar 1, 2004	Jun 1, 2005	Prevention of Acute Rejection After Kidney Transplantation
NCT00239057	Phase 3	Completed	May 1, 2002	Jan 1, 2005	Maintenance Renal Transplantation
NCT00239031	Phase 3	Completed	Mar 1, 2002	Jul 1, 2005	Denovo Renal Transplantation
NCT00574743	Approved	Completed	Jan 1, 2002	—	Heart Transplantation

Competing Products

20 competing products in Autoimmune Disease

See all competitors

Product	Company	Stage	Hype Score
Satralizumab	Chugai Pharmaceutical	Phase 3	77
SHR0302 quick release tablets + SHR0302 sustained-release tablets	Jiangsu Hengrui Medicine	Phase 1	33
HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu Hengrui Medicine	Phase 1	33
HR19042 Capsules	Jiangsu Hengrui Medicine	Phase 2	52
Ianalumab + Placebo	Novartis	Phase 3	77
VAY736	Novartis	Phase 2/3	65
remibrutinib	Novartis	Phase 1	33
RO7049665	Roche	Phase 2	52
rituximab (Mabthera®) + Placebo	Roche	Phase 3	77
NovoMix 30 + Tablet treatment	Novo Nordisk	Pre-clinical	22
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)	Swedish Orphan Biovitrum	Phase 2	51
branebrutinib + abatacept + branebrutinib placebo	Bristol Myers Squibb	Phase 2	51
BMS-986165	Bristol Myers Squibb	Phase 1	32
Nivolumab	Bristol Myers Squibb	Phase 1	32
Fludarabine + Cyclophosphamide + Tocilizumab	Bristol Myers Squibb	Phase 1	32
BMS-986165 + Rosuvastatin	Bristol Myers Squibb	Phase 1	32
SAR445088	Sanofi	Phase 1	32
BIVV020	Sanofi	Phase 1	32
rilzabrutinib	Sanofi	Phase 2	51
rilzabrutinib + placebo	Sanofi	Phase 3	76

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved